On July 2, Everest Medicines (1952.HK), a Hong Kong-listed innovative pharmaceutical company, announced that its new generation of covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor EVER001 (XNW1011), for which it has global rights, has obtained positive latest interim data in a Phase 1b/2a clinical trial for the treatment of primary membranous nephropathy (pMN). The data showed that EVER001 continued to demonstrate excellent efficacy and safety during the extended follow-up period. Driven by these excellent clinical data, the development of EVER001 is expected to accelerate. Based on the current positive clinical data, experts recommend communicating directly with the U.S. Food and Drug Administration (FDA) to initiate Phase III clinical studies, and simultaneously communicate with the China Food and Drug Administration (CDE). Clinical trial data highlights frequently, with both effectiveness and safety According to reports, the Phase 1b/2a clinical trial of EVER001 for the treatment of primary membranous nephropathy conducted in China ...
Recently, the official website of the National Medical Products Administration (NMPA) announced that Jinbeixin (Fuxinqibaimab), a Class 1 innovative drug independently developed by Jinsai Pharmaceutical, has been officially approved for marketing. It is suitable for patients with acute attacks of gouty arthritis in adults who are contraindicated, intolerant or ineffective to non-steroidal anti-inflammatory drugs and/or colchicine, and who are not suitable for repeated use of steroid hormones. With the three major clinical advantages of ” long-term control, rapid and effective, and safe and reliable “, Jinbeixin is expected to become the largest single product in the field of autoimmune disease treatment in China, meet huge market demand, and escort the majority of gout patients! Gout is known as the “king of pain”. According to the “2021 China Hyperuricemia and Gout Trend White Paper”, there are approximately 177 million patients with hyperuricemia in China, and more than 14.66 million patients with ...
On July 3, Lianhuan Pharmaceutical(600513) announced that the company has recently conducted a specific object survey with a number of investment institutions. The event was held in Beijing on July 2, 2025, and the participating units included China Asset Management, China Canada Fund and Shibei Investment. The company’s director and general manager Niu Ben and the director of the board office Ge Kai received investors and introduced the company’s development history, technical cooperation and the progress of the projects under research. The LH-1801 project mentioned in the announcement is an SGLT2 inhibitor jointly developed by the company and the Shanghai Institute of Materia Medica, Chinese Academy of Sciences. The project has now entered the Phase III clinical trial stage. It is expected that key data will be obtained in the first quarter of next year and an application for listing will be submitted to the National Medical Products Administration in ...
On May 12, 2025, Tianjin Zhonghe Gene Technology Co., Ltd. (hereinafter referred to as Zhonghe Gene) and Tianjin Tianbao Holding Co., Ltd. signed a DNA synthesis project. This marks that the new generation of DNA synthesis technology – enzymatic DNA biosynthesis technology has officially stepped into industrialization, injecting new momentum of “Intelligent Manufacturing in China” into the field of synthetic biology. It is understood that DNA synthesis technology is a key common underlying technology and core enabling technology in synthetic biology. Its synthesis principles are mainly divided into chemical methods and biological methods, and the existing commercialized DNA synthesis technologies and equipment are mainly based on chemical methods. At present, the synthesis length and cost of chemical DNA synthesis methods have reached their limits. However, this technology still has problems such as low single-step accuracy, cumbersome steps for long-fragment DNA synthesis, high synthesis cost, and environmental pollution, which restrict the ...
From June 24 to 25, during the 23rd World Pharmaceutical Raw Materials China Exhibition, the 14th Forum on Innovation and Development of the Pharmaceutical Industry was successfully held in Shanghai. This forum conducted special discussions on hot topics such as the trends of economic and trade restriction measures of the U.S. Trump administration, underwriting and risk analysis of the biopharmaceutical industry chain, review and analysis of China’s pharmaceutical industry development during the “14th Five-Year Plan” and outlook on the development situation during the “15th Five-Year Plan”, the impact and trend prediction of new policies on the pharmaceutical industry, the main characteristics of current pharmaceutical industry development, the development status of China’s generic drug industry, the trends and strategies of pharmaceutical companies entering emerging markets, countermeasures for Chinese export enterprises under the background of Sino-U.S. trade frictions, and the core advantages of industrial parks. Luo Yang, Deputy Secretary-General of the China ...
On the afternoon of June 10, a delegation of over 10 people, including Professor Muhammad Iqbal Chaudhry, Coordinator General of the Cooperation-Ministerial Standing Committee on Scientific and Technological Cooperation of the Organization of Islamic Cooperation (OIC-COMSTECH), Maggie Lowe, an official from the Commercial Section of the Embassy of Pakistan in China, and Professor Liu Xinmin, Advisor on Traditional Medicine of the World Health Organization and Coordinator for Traditional Chinese Medicine of OIC-COMSTECH, visited the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE). They held discussions and exchanges with Secretary Meng Dongping of the Chamber and other representatives. The two sides engaged in extensive and lively exchanges on strengthening cooperation between China and the Organization of Islamic Cooperation in the field of traditional medicine under the framework of the SCO Traditional Medicine Industry Alliance, promoting China-Pakistan cooperation in traditional medicine, and facilitating the integration of ...
On June 25, 2025, the “Exchange Meeting for Assisting Chinese Enterprises in Entering Pharmaceutical Markets of Low – and Middle – Income Countries” co – hosted by the China Chamber of Commerce for Import and Export of Medicines and Health Products (CCCMHPIE) and the Medicines Patent Pool (MPP) – a global health organization supported by the United Nations – successfully concluded at the Shanghai New International Expo Center. The event gathered experts from MPP, the United Nations International Drug Purchase Facility (UNITAID), and over 50 Chinese pharmaceutical companies to jointly explore strategic paths for tapping into the global pharmaceutical blue – ocean market with a population of 4.5 billion through innovative international cooperation mechanisms. President Zhou Hui of CCCMHPIE and Dr. Judith Federhofer, Director of Business Development at MPP, attended the forum and delivered speeches. Director Zhang Beibei of the Legal and Comprehensive Department presided over the forum. I. Breaking ...
The pharmaceutical industry took some time to put sustainable development on the management agenda. However, the industry is now going all out to catch up – with strong support from Zeta. This solution provider is helping the pharmaceutical industry with its low-carbon transformation through its net-zero roadmap and a new business line. Since the EU announced the “European Green Deal”, one thing has become clear: all industries must work together to achieve the goal of zero emissions. The pharmaceutical industry has been slow to progress. But now, pressure from investors and shareholders has prompted leaders in the pharmaceutical and biotechnology industries to pick up the pace. Green energy, sustainable supply chains, and decarbonization of production and bases – many companies are now embarking on the path of green transformation. This can be seen from the sustainable development goals set by industry giants such as Novartis, GSK, or Roche, as well ...
Drugdu.com expert’s response: Whether overdue large-scale equipment can continue to be used requires discussion based on equipment type. Medical devices are strictly prohibited from being used beyond their expiration dates, special equipment can be extended for use only after passing inspection or assessment and undergoing registration changes, while other equipment should be decided upon after a comprehensive evaluation of safety risks. The specific analysis is as follows: Medical Devices: Strictly Prohibited from Being Used Beyond Expiration Dates Legal Basis: According to Article 39 of the Regulations on the Supervision and Administration of Medical Devices and Article 10 of the Provisions on the Management of Instructions and Labels for Medical Devices, the instructions and labels of medical devices must indicate the production date, service life, or expiration date. Continuing to use medical devices beyond their marked expiration dates will result in administrative penalties, including confiscation of illegally produced, operated, or used medical devices, fines, ...
On the evening of July 2nd, Baili Tianheng announced that its independently developed EGFR × HER3 dual antibody ADC (iza bene), which is a first in class, new concept, and the only one to enter the Phase III clinical stage, has reached the primary endpoint in the Phase III clinical trial of nasopharyngeal carcinoma (study protocol number: BL-B01D1-303). The indication is for recurrent or metastatic nasopharyngeal carcinoma that has been previously treated with PD-1/PD-L1 monoclonal antibodies and has failed at least two lines of chemotherapy (at least one line containing platinum). The announcement shows that Iza bren is conducting over 40 clinical trials targeting multiple types of tumors in China and the United States. As of now, Iza bren has 5 indications included in the breakthrough treatment list by the Drug Evaluation Center of the National Medical Products Administration. Baili Tianheng presented Phase I research data on Iza bren treatment ...
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.